Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Kim Kardashian

AstraZeneca AZ

Trials of AZ’s durvalumab restart as FDA hold is relaxed

Bleeding side effects in two head and neck cancer studies not attributed to the PD-L1 inhibitor

- PMLiVE

GSK files first application for triple COPD therapy

Submits combo in the US one year early to coincide with EU marketing application

- PMLiVE

The rise and rise of Generation Now

Investigating the positive changes millennials are bringing to healthcare

- PMLiVE

Takeda and Marvel launch IBD superhero squad

The comic book initiative aims to raise awareness of the gastrointestinal disease

Novartis building

Novartis gets speedy FDA review for midostaurin

Leukaemia treatment could become first targeted therapy for 25 years

- PMLiVE

A rock and a hard place

When insurance companies exclude drugs from their coverage

Eli Lilly HQ

Lilly bags EU approval for cancer treatment Lartruvo

Licensed for use with doxorubicin for soft tissue sarcoma patients

PatientsLikeMe launches ‘virtual trial’ in ALS

Partners with The Duke ALS Clinic on study of the Soy Peptide Lunasin

- PMLiVE

MHRA launches medicines side effects awareness drive

Creates social media campaign as part of EU-wide initiative

Sanofi reception

Manufacturing issues scupper Sanofi’s sarilumab launch plans

FDA turns down the rheumatoid arthritis drug’s marketing application after routine inspection

- PMLiVE

Turning healthcare on its head

Efforts to deliver patient-centric care are turning healthcare communications on its head

AstraZeneca AZ

AstraZeneca shaken by FDA partial hold on durvalumab trial

Aims to resume trial recruitment as soon as possible after bleeding side effects curb study

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links